Collection's Items (Sorted by Submit Date in Descending order): 21 to 40 of 41
| Issue Date | Title | Author(s) |
| 2020-12 | Survival outcomes for plasmablastic lymphoma: an international, multicentre study by the Australasian Lymphoma Alliance. | Yannakou, Costas; Polizzotto, Mark; Cwynarski, Kate; Burton, Cathy; Jiamsakul, Awachana; Bower, Mark; Kuruvilla, John; Montoto, Silvia; McKay, Pam; Osborne, Wendy; Miliken, Sam; Linton, Kim; Manos, Kate; Kassam, Shireen; Doo, Nicole; Watson, Anne-Marie; Fedele, Pasquale; Hunt, Stewart; Renshaw, Hanna; Thakrar, Nisha; Smith, Alexandra; Painter, Daniel; Maxwell, Alice; Liu, Qin; Dhairyawan, Rageshri; Ferguson, Graeme; Pickard, Keir; Hamad, Nada | |
| 2020-07 | Prolonged lymphopenia and infection risk is mitigated by antimicrobial prophylaxis in patients with indolent non-Hodgkin Lymphoma (iNHL) treated with bendamustine +/- anti-CD20 antibody: the Australian Lymphoma Alliance experience. | Yannakou, Costas; Manos, Kate; Lasica, Masa; Grigg, Andrew; Di Ciaccio, Pietro; Wong, Jonathan; Sekaran, Usha; Wight, Joel; Goh, Zhong; Jina, Hayden; Butler, Llewyn; Hamad, Nada; Gregory, Gareth; Gangatharan, Shane; Cochrane, Tara; Piper, Kristen; Churilov, Leonid; Hawkes, Eliza | |
| 2020-10 | Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukaemia and follicular lymphoma. | Prince, Miles; Tam, Constantine; Quach, Hang; Nicol, Andrew; Badoux, Xavier; Rose, Hannah; Leahy, Michael; Wickham, Nicholas; Patil, Sushrut; Huang, Jane; Prathikanti, Radha; Cohen, Aileen; Elstrom, Rebecca; Reed, William; Schneider, Jingjing; Flinn, Ian | |
| 2020-10 | T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. | Prince, Miles; Ghione, Paola; Faruque, Promie; Mehta-Shah, Neha; Seshan, Venkatraman; Ozkaya, Neval; Bhaskar, Shakthi; Yeung, James; Spinner, Michael; Lunning, Matthew; Inghirami, Giorgio; Moskowitz, Alison; Galasso, Natasha; Ganesan, Nivetha; van der Weyden, Carrie; Ruan, Jia; Trotmani, Judith; Advani, Ranjana; Dogan, Ahmet; Horwitz, Steven | |
| 2020-05 | Safety and activity of the once daily selective Bruton Tyrosine Kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukaemia (CLL) and lymphoma. | Yannakou, Costas; Chan, Cheah; Wickham, Nicholas; Lewis, Katharine; Hui, Chi-Hung; Tang, Pek; Turpuseema, Tejasvi; Miskin, Hari; Tang, Jian-Ping; Normant, Emmanuel; Ricart, Alejandro; Tam, Constantine | |
| 2020-11 | Survival outcomes for plasmablastic lymphoma: an international, multicentre study by the Australasian Lymphoma Alliance (ALA) | Yannakou, Costas; Di Ciaccio, Pietro; Polizzotto, Mark; Cwynarski, Kate; Burton, Cathy; Jiamsakul, Awachana; Bower, Mark; Kuruvilla, John; Montoto, Silvia; McKay, Pam; Osborne, Wendy; Milliken, Sam; Linton, Kim; Manos, Kate; Kassam, Shireen; Doo, Nicole; Watson, Ann-Marie; Fedele, Pasquale; Hunt, Stewart; Renshaw, Hanna; Thakrar, Nisha; Smith, Alexandra; Painter, Daniel; Maxwell, Alice; Liu, Qin; Dhairyawan, Rageshri; Ferguson, Graeme; Pickard, Keir; Hamad, Nada | |
| 2019-08 | Characterisation of the immune evasion phenotype of Richter Syndrome and the implications for immune checkpoint therapy. | Yannakou, Costas; Gould, Clare; Lickiss, Jennifer; Kankanige, Yamuna; Yerneni, Satwica; Markham, John; Villa, Diego; Slack, Graham; Chin, Collin; Tam, Constantine; Lade, Stephen; Nelson, Niles; Neeson, Paul; Seymour, John; Dickinson, Michael; Westerman, David; Blombery, Piers | |
| 2020-07 | Clinical activity of TG-1701, as monotherapy and in combination with Ublituximab and Umbralisib (U2), in patients with B-cell malignancies. | Yannakou, Costas; Chan, Cheah; Wickham, Nick; Jurczak, Wojciech; Lasica, Masa; Wrobel, Tomasz; Lewis, Katharine; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari; Tang, Jian-Ping; Normant, Emmanuel; Ricart, Alejandro; O'Connor, Owen; Tam, Constantine | |
| 2020-10 | Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70)is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies | Prince, Miles; Leleu, Xavier; Beksac, Meral; Chou, Takaaki; Dimopoulos, Meletios; Yoon, Sung-Soo; Pour, Ludek; Shelekhova, Tatiana; Chari, Ajai; Khurana, Monica; Zhang, Jianqi; Obreja, Mihaela; Qi, Ming; Oriol, Albert; Siegel, David | |
| 2020-10 | Role of haematopoietic stem cell transplantation in peripheral T-Cell lymphoma. | Yannakou, Costas; Prince, Miles; Abeyakoon, Chathuri; van der Weyden, Carrie; Harrop, Sean; Khot, Amit | |
| 2020-11 | CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma. | Yannakou, Costas; Khodadoust, Michael; Feldman, Tatyana; Yoon, Dok; Radeski, Dejan; Kim, Youn; Mehta Shah, Meta; Khot, Amit; Wilcox, Ryan; King, Won; Horwitz, Steven; Buggy, Joseph; Hotson, Andrew; Hill, Craig; Munneke, Brian; Mahabhashyam, Suresh; Miller, Richard; Janc, James; Mobasher, Merhdad | |
| 2021 | TG-1701, A selective Bruton Tyrosine Kinase (BTK) Inhibitor, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients with B- Cell malignancies. | Yannakou, Costas; Chan, Cheah; Wojciech, Jurczak; Lasica, Masa; Wickham, Nicholas; Wrobel, Tomasz; Andrzej, Jan; Cheung, Stanley; Lewis, Katharine; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari; Tan, Jian-Ping; Normant, Emmanuel; O'Connor, Owen; Ricart, Alejandro; Tam, Constantine | |
| 2021-06 | First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs). | Yannakou, Costas; Prince, Miles; Ailawadhi, Sikander; Chanan-Khan, Asher Alban Akmal; Chen, Zi; Huang, Bo; Konopleva, Marina; Brander, Danielle; Rizzieri, David; Lasica, Masa; Tam, Constantine Si Lun; Davids, Matthew; He, Zhicong; Lu, Ming; Ahmad, Mohammad; Li, Mingyu; Liang, Zhiyan; Mudenda, Boyd; Yang, Dajun; Zhai, Yifan | |
| 2021-05 | Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies. | Yannakou, Costas; Cheah, Chan; Jurczak, Wojciech; Lasica, Masa; Wickham, Nicholas W.; Wrobel, Tomasz; Andrzej Walewski,, Jan; Cheung, Stanley; Lewis, Katharine L.; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari P.; Tang, Jian-Ping; Normant, Emmanuel; O'Connor, Owen A.; Ricart, Alejandro Daniel; Tam, Constantine Si Lun | |
| 2021-05 | Management of hydroxyurea resistant or intolerant polycythemia vera. | Prince, Miles; Raman, Indu; Yannakou, Costas; Pasricha, Sant-Rayn | |
| 2020-10 | A novel germline splice site DDX41 mutation causing MDS/AML. | Piggin, Anna; Fox, Lucy; Prince, Miles | |
| 2019-08 | Molecular profiling of thyroid fine needle aspiration samples: initial validation study. | Yannakou, Costas; Prince, Miles; Lee, James Cheng-Yen; Yellapu, Bhargavi; Fellowes, Andrew; Fox, Stephen | |
| 2019-08 | Establishing a biobank in a private hospital setting: successes and lessons learnt. | Epworth Centre for Immunotherapies and Snowdome Laboratories; Le, Caroline; Johnston, Hayley; Brooks, Nicole; Fox, Lucy; Prince, Miles; Yannakou, Costas | |
| 2019-03 | Molecular drivers of breast implant-associated anaplastic large cell lymphoma | Blombery, Piers; Prince, Miles; Thomas, E. R. | |
| 2019-01 | FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformation. | Prince, Miles; Douglas, Abby; Mohammad, Atarod | |
Collection's Items (Sorted by Submit Date in Descending order): 21 to 40 of 41
